Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.
about
Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based reviewNonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversalPerioperative management of patients on direct oral anticoagulants.Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.Management of non-vitamin K antagonist oral anticoagulants in the perioperative settingClinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence.Interrupting anticoagulation in patients with nonvalvular atrial fibrillation.Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug ConcentrationsRivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants.Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillationSpontaneous Intracerebral Hemorrhage: Management.Transitioning to and from the novel oral anticoagulants: a management strategy for clinicians.Interpretation of coagulation test results under direct oral anticoagulants.New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.Monitoring and reversal strategies for new oral anticoagulants.Management of peri-operative anti-thrombotic therapy.Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.Practical issues in the management of novel oral anticoagulants-cardioversion and ablation.Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs).Assessing nonvitamin K antagonist oral anticoagulants (NOACs) in the laboratory.New oral anticoagulants - a practical guide.Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants.Laboratory measurement of the direct oral anticoagulants.Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis.Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme.New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention.The Effects of Indirect- and Direct-Acting Anticoagulants on Lupus Anticoagulant Assays: A Large, Retrospective Study at a Coagulation Reference Laboratory.Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal.An Assessment of the State of Current Practice in Coagulation Laboratories.Prothrombin complex concentrate for the management of severe traumatic bleeding in a patient anticoagulated with apixaban.Practical management of patients on apixaban: a consensus guide.Prothrombin Time Tests for the Monitoring of Direct Oral Anticoagulants and Their Evaluation as Indicators of the Reversal Effect.Comparison of prothrombin time tests used in the monitoring of edoxaban and their evaluation as indicators of the reversal effect.Main considerable factors for correct laboratory test interpretation under DOA treatment.Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology.Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants.Real-world monitoring of direct oral anticoagulants in clinic and hospitalization settings.
P2860
Q26783455-D3A95958-E97A-46E1-A93E-E485415BCE31Q28071657-E13D0981-373F-43C6-B236-BF88542FBC36Q33692054-2DC320F2-C156-43C0-91EC-69C96F18F7F1Q33854667-22CDAEC8-F78E-4C72-9D7F-A0B7EA113D7AQ34207558-12B55DE1-C9D6-4E8D-A126-F5681536E99BQ34482427-E2FDC1B1-F71F-4874-A72A-D05720B7F7FCQ34688742-A29AFADA-AABA-4894-B606-CFBC4AF008D0Q35154142-93D388E4-BCB2-4DB0-AD42-16BC1D6D40E5Q35674404-CF014A88-6A32-4CA3-AE7D-FBBA9165A490Q36331126-743E49AD-0F7D-405A-906B-DF250410605AQ36458797-5FAF8DB4-8E50-48A2-9E4E-427866CDD831Q36594607-4E0DEFF2-5AA3-4BA0-BB27-15C23631421AQ37640888-4B9BE936-7A89-4FD2-A3B9-7CDF11572BB8Q38187043-3D639DD0-E84E-4A09-A7EA-A62126ADEE2FQ38205947-08811939-B689-4A88-B098-7940A5B659CCQ38221642-870FB0B4-8F22-461B-88CE-A9DCBFA1B2BBQ38272325-DC5AC7B0-BA81-4558-A3F4-20A163646CDBQ38273789-B24800CE-F64D-4B95-B04E-BC2D0706CFFEQ38287151-F262AC7D-AD29-4631-B340-B0D67EE5E527Q38365022-B9268845-76D7-43CA-83F3-AAEB81DFE8C1Q38458642-3DAD70D2-1542-4182-8DE6-586629459AB1Q38481929-28CFFDA5-B4C6-4B52-AD5A-D4275615441DQ38580072-129BB832-4F24-46C1-9D1E-B86F228DA2A5Q38608242-51B64A49-0CB9-489E-98EA-60F32A28E7CDQ38613869-712CB81E-EBA8-40EF-9B91-180EC7BC5D6BQ38777127-798F7E9D-2482-4223-9B30-B14BAEF786E1Q38901666-95ADF575-105D-4F28-8616-79651DE88C78Q39027027-3C243027-C7FB-4542-A5C8-3103C5C03758Q39318344-C88991B8-32CD-405D-9970-25DF192FC21BQ39452481-2BABF5F0-71B0-4D5C-8BB9-4EFFFD4473DDQ40093269-0E16711A-116C-4FF3-A797-5D58A703C583Q40200718-39290AB6-F8D6-4650-8F99-10FFE3D27F87Q41890211-018E1722-54E8-4252-8F4F-AD5A91910C0EQ41947735-6BC8F40D-ABA9-4EA2-8924-282BA94010B2Q41947739-B224D47A-29F9-4309-990D-5FC9A35054E1Q42862770-368185C7-EBCC-47F3-A3D8-85A1F84EBBAAQ45857724-DC0D00F4-9010-4E7F-B18C-CDBE7FE80740Q45865979-8FE31E65-65FB-407E-AA9B-88AA09FA8A11Q47155567-9BD706FA-9646-4122-938A-CACCAC2AFBB6Q47161289-A66AAFA7-6C0F-484E-962E-9FF3C437D068
P2860
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Impact of apixaban on routine ...... a practical laboratory guide.
@en
Impact of apixaban on routine ...... a practical laboratory guide.
@nl
type
label
Impact of apixaban on routine ...... a practical laboratory guide.
@en
Impact of apixaban on routine ...... a practical laboratory guide.
@nl
prefLabel
Impact of apixaban on routine ...... a practical laboratory guide.
@en
Impact of apixaban on routine ...... a practical laboratory guide.
@nl
P2093
P356
P1476
Impact of apixaban on routine ...... : a practical laboratory guide
@en
P2093
Bernard Chatelain
Christian Chatelain
Jean-Michel Dogné
P304
P356
10.1160/TH12-12-0898
P577
2013-06-13T00:00:00Z